Advertisements

ANNITA

Quick links to important sections

ANNITA

Advertisements
Advertisements

Method of action: Antiparasitic

Treatment option: Diarrhea

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of ANNITA

Quick Facts About ANNITA

Property Description
Active ingredient Nitazoxanide (metabolizes to Tizoxanide)
Form Tablets and Oral Suspension
Pharmacological class Antiprotozoal Agent, Thiazolide
General Purpose Countering parasitic infections (e.g., protozoa and helminths)
Origin Synthetic compound

What Type of Medicine is ANNITA (Nitazoxanide)?

ANNITA is a prescription-only medication containing the active substance Nitazoxanide, a synthetic compound belonging to the thiazolide chemical class. Following oral administration, Nitazoxanide is rapidly converted into its principal circulating form, the active metabolite Tizoxanide. The medication is officially classified as an Antiprotozoal Agent.

Nitazoxanide's activity against both single-celled organisms (protozoa) and various parasitic worms (helminths) establishes it as a broad-spectrum agent. Its specific chemical structure allows it to target a wide range of protozoal and helminthic infections.


Composition and Available Forms of ANNITA

The product is a single-ingredient medication, containing Nitazoxanide as the source of pharmacological activity, along with necessary pharmaceutical excipients. It is manufactured for oral administration and is available in two primary dosage forms: a solid tablet and a liquid powder for oral suspension.

The availability of both a liquid suspension and a solid tablet form ensures that the medicine can be delivered to diverse patient populations, including those who may have difficulty swallowing tablets.


What is the General Purpose of Antiprotozoal Agents?

The primary purpose of this type of medicine is to clear the body of parasitic infections by disrupting the survival mechanisms of the pathogens. This anti-parasitic action occurs when the active metabolite, Tizoxanide, interferes with the Pyruvate Ferredoxin Oxidoreductase (PFOR) enzyme, which is essential for the pathogen's ability to generate energy.

This targeted interference prevents the growth and survival of susceptible protozoa and helminths. The inhibition of PFOR is a central mechanism against anaerobic energy metabolism in various microorganisms, facilitating the treatment of parasitic disease.

Regulatory References

  1. Nitazoxanide DailyMed Label (NIH/NLM)
Advertisements

What side effects are possible with ANNITA?

Official Safety Profile and Adverse Reactions

The safety profile of Nitazoxanide (ANNITA) is established through clinical data and post-marketing surveillance, classifying possible effects by frequency and the organ systems involved, as is standard in regulatory documents.

Adverse Reaction Scope
Frequency Classification Adverse reactions are primarily classified as Common (occurring in 1% to <10% of patients) in official labeling.
System-Organ Classes Effects most commonly involve Gastrointestinal disorders (e.g., abdominal pain, nausea, vomiting) and Nervous system disorders (e.g., headache). Effects on Renal and urinary disorders (e.g., chromaturia, or change in urine color) are also documented.
Serious Adverse Reactions Documentation includes reports of rare but serious events such as severe hypersensitivity reactions and anaphylaxis from post-marketing safety data.

Population-Specific Safety Constraints

The medicine is subject to regulatory constraints in specific patient populations due to limited data:

  • Infants: Safety and effectiveness have not been established for use in pediatric patients under 12 months of age.
  • Renal or Hepatic Impairment: The drug's safety in individuals with severe hepatic or renal disease has not been adequately studied, leading to a constraint on its use in these populations.

Safety-Related Restrictions

Use of the medicine is contraindicated in individuals with a known hypersensitivity to Nitazoxanide or any other ingredient in the formulation. Furthermore, severe kidney or liver impairment places a restriction on the use of this medicine due to a lack of complete safety data. The official safety information structures the understanding of risk by clearly categorizing frequently observed, generally temporary effects, while also explicitly documenting rare, severe reactions and defining limitations on use in vulnerable populations.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for ANNITA (Nitazoxanide) overdose is defined by limited specific data and a mandatory focus on supportive medical management. The prescribing information notes that limited clinical information on overdosage is available, although single oral doses up to 4000 mg administered to healthy adult volunteers did not produce significant adverse effects.

When to Seek Urgent Help

Immediate medical attention is necessary for any suspected overdose. Emergency services must be contacted immediately if the person who has overdosed has collapsed, had a seizure, has trouble breathing, or cannot be awakened, as directed by official government guidance.

Management and Procedural Notes

In the event of an overdose, patients must be observed and provided with symptomatic and supportive treatment. The regulatory label confirms that there is no specific antidote for this drug. Procedurally, gastric lavage may be appropriate soon after the oral administration of the overdose. Due to the high protein binding (greater than 99.9%) of the active metabolite, regulatory sources indicate that dialysis is unlikely to significantly reduce plasma concentrations of the drug.

Advertisements

Therapeutic Uses of ANNITA

What ANNITA Treats: Main Uses and Benefits

ANNITA is commonly used to help manage diarrhea caused by two specific protozoal infections: Giardiasis (Giardia lamblia) and Cryptosporidiosis (Cryptosporidium parvum). This medication is relevant in contexts marked by increased discomfort to support the clearance of these pathogens. The primary therapeutic benefit is in treating the underlying condition, which supports general well-being during symptomatic phases.

The medication is applied for managing the symptoms related to heightened physiological activity such as acute and persistent diarrhea and the associated abdominal discomfort and cramping. This usage is common in clinical settings where the infection is linked to contaminated water or travel-related exposure.

“It provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.”

By supporting the management of these manifestations, the treatment assists with maintaining functional stability for immunocompetent patients, including adults and children over one year of age.


Quick Fact: Relief for Acute Diarrhea
Main Conditions: Giardiasis and Cryptosporidiosis
Primary Symptom Focus: Acute and persistent diarrhea
Patient Benefit: Supports clearance and functional stability

Regulatory References

  1. Official FDA Prescribing Information on DailyMed
Advertisements

Eligibility and Restrictions for Use

Official Population Eligibility for ANNITA

The eligibility to use ANNITA (Nitazoxanide) is strictly governed by regulatory labeling and is based on age, formulation, and underlying health status. This medicine is primarily intended for use in immunocompetent patients.

Eligibility Status Regulatory Requirement
Contraindicated Patients with a prior hypersensitivity reaction to Nitazoxanide or any ingredient in its formulations must not use this medicine.
Age-Specific Use The Oral Suspension is approved for pediatric patients one year of age and older. The 500 mg Tablets are restricted to patients 12 years of age and older and must not be given to children 11 years or younger. Safety and efficacy are not established in infants under one year.
Conditional Use Use with caution is required in patients with compromised hepatic or renal function, as the drug's processing is not formally studied in these conditions.

Population-Specific Limitations The medication has not been shown to be effective for Cryptosporidium parvum in HIV-infected or immunodeficient patients. For pregnancy, there are no human data to determine a drug-associated risk, making use conditional. It is not known if the active metabolite is secreted during lactation, requiring professional consideration.

Advertisements

What should I know about interactions with other medicines?

ANNITA Interactions with other medicines and products

ANNITA’s official interaction profile is defined by pharmacokinetic findings, primarily the high plasma protein binding of its active metabolite, Tizoxanide, and a notable drug-food interaction.

Interaction Type Regulatory Finding
Highly Protein-Bound Drugs Potential for competition for binding sites with other medicinal products that are also highly protein-bound and have a narrow therapeutic index.
Specific Example Regulatory documents cite Warfarin as an example where co-administration requires monitoring for adverse reactions due to the potential for binding site competition.
Cytochrome P450 (CYP) Enzymes No significant interaction is expected with medicinal products metabolized by or inhibiting major CYP enzymes (CYP1A2, CYP2D6, CYP3A, CYP2C9, and CYP2C19).

Interactions with Products and Conditions

The co-administration of the ANNITA tablet formulation with food results in a significant pharmacokinetic modification, increasing the systemic exposure ( AUC) of the active metabolite, Tizoxanide, by almost two-fold. This drug-food interaction also elevates the maximum plasma concentration ( C max) by approximately 50%. No specific administration timing separation rules are formally documented for co-administration with other medicines. Regarding specific populations, regulatory documents indicate that the pharmacokinetics of the medicine in individuals with compromised renal or hepatic function have not been studied.

Advertisements

Mechanism of Action

How ANNITA Works

ANNITA’s pharmacological activity is driven by its active metabolite, Tizoxanide, through a selective toxicity mechanism targeting metabolic processes absent or distinct in host cells. The mechanism operates across three key domains.

Targeted Blockade of Parasite Energy Production

Against protozoa and anaerobic bacteria, Tizoxanide acts as a non-competitive inhibitor of the Pyruvate:ferredoxin/flavodoxin oxidoreductase (PFOR) enzyme. PFOR is crucial for the parasite's anaerobic energy metabolism. Inhibition of this enzyme interrupts the essential flow of reducing equivalents, initiating a cascade that results in intracellular energy depletion and the cessation of core metabolic function in the parasite.

Dual Interference with Helminthic Viability

Against parasitic worms, Tizoxanide exhibits a dual action. It modulates specific glutamate-gated chloride ion channels in the worm's neuromuscular system, which disrupts motor signaling and causes functional paralysis. Concurrently, it inhibits the Glutathione-S-transferase (GST) enzyme, compromising the parasite's ability to detoxify and withstand internal host defenses.

Mechanistic Selectivity and Functional Constraint

The drug’s selectivity derives from its action on targets (PFOR, Avr-14) that are either unique to or structurally divergent within the parasite, contrasting with corresponding structures in human cells. This targeted mechanism confines its energy-blocking and neural-disrupting effects predominantly to the parasitic organisms.

Advertisements

Dosage and Administration Information

How to Use ANNITA (Nitazoxanide)

ANNITA is a prescription-only medicine administered via the oral route, available as a 500 mg tablet or as a 100 mg/5 mL oral suspension for patients who require liquid dosing. The usage protocol is defined by a fixed, short-term course, requiring specific timing in relation to meals.

Dosing and Treatment Schedule

Administration is scheduled every 12 hours (twice daily) for a fixed course of 3 days across all approved age groups. The medicine must be taken with food to ensure maximum absorption of the active metabolite into the bloodstream.

Patient Population Dose per Administration Dosage Form Requirement
Adults and Adolescents (12 years) 500 mg Tablet or Oral Suspension
Children (4–11 years) 200 mg Oral Suspension only
Children (1–3 years) 100 mg Oral Suspension only

Administration Requirements

ANNITA tablets are not to be administered to children 11 years of age or younger. The oral suspension is required for pediatric patients to ensure proper dose delivery. If the suspension is used, the reconstituted liquid must be shaken well before each dose is measured. If a dose is missed, it should be taken as soon as possible, but two doses should not be taken at the same time; the regular schedule should be resumed by skipping the missed dose if it is almost time for the next scheduled dose.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for ANNITA

The research for ANNITA (nitazoxanide) involves clinical studies designed to understand the patterns observed in individuals with specific parasitic infections. This overview describes the research scenarios that have been explored and the structure of the evidence, while always reflecting the limitations and uncertainties inherent in the current evidence.

Evidence for Use in Diarrhea Caused by Giardia lamblia

ANNITA was studied for use in conditions associated with acute or disruptive episodes, specifically diarrhea caused by the parasite Giardia lamblia. The majority of the primary research exploring this indication involved short-term randomized, controlled trials (RCTs). These studies typically involved immunocompetent individuals, including both children and adults with a confirmed diagnosis of Giardiasis.

Research reports described measurements related to parasite status in stool samples (parasitological response) and the patterns observed in patient-reported outcomes describing perceived discomfort. Studies that included other active treatments reported comparable measured outcomes related to parasite status and symptom patterns. However, data characterizing the durability of the parasite's status or long-term effects are not fully established.

Evidence for Use in Diarrhea Caused by Cryptosporidium parvum

Research exploring conditions characterized by fluctuating or episodic manifestations, such as Cryptosporidiosis, included controlled trials and observational settings. These studies focused primarily on immunocompetent children with confirmed infection. Researchers examined the patients’ stool samples to measure the status of Cryptosporidium oocysts and monitored clinical outcomes related to physical discomfort.

Research describes measurements recorded during the study period in pivotal trials involving immunocompetent children. However, research that evaluated severely immunocompromised individuals, such as those with advanced HIV infection, described results that were inconsistent. Findings described patterns where both parasitological and clinical measured outcomes were inconsistent in these study populations.

Research Gaps and Areas of Uncertainty

Clinical trials for both indications have typically focused on short-term symptom changes. Follow-up durations were limited in most key studies, meaning the stability of the response over an extended period and the durability of symptom change are not well characterized by the existing evidence. Furthermore, data for certain study groups, such as severely immunocompromised individuals, remain limited, and the measured results reflect only the specific conditions under which the studies were conducted. More research is ongoing to better understand the full landscape of ANNITA's use.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about ANNITA (FAQ)

Q: Is ANNITA used for anything else besides its main purpose?

Official regulatory documents indicate that ANNITA is only indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in specific patient populations. The official prescribing information does not list other uses.


Q: Is there a different name or brand name for ANNITA?

According to official product information, the active ingredient is known by the generic name nitazoxanide. The brand name mentioned in regulatory labels is ALINIA®.


Q: Can ANNITA be stopped suddenly, or does it need to be tapered?

Official regulatory information advises that the medicine is not to be discontinued without consulting a healthcare provider, even if symptoms begin to improve. The full, short course is described as needing to be completed as directed.


Q: Are the common side effects of ANNITA usually temporary?

Official guidance on common, expected effects notes that they are often temporary. For instance, a documented change in urine color is usually described as harmless and observed to resolve after the full treatment course has been completed.


Q: Do most people experience side effects when taking ANNITA?

Official safety data classifies common adverse effects, such as abdominal pain and nausea, as those occurring in 1% to 10% of patients. This frequency means that these particular common effects were reported in a small percentage of individuals in clinical studies.


Q: Does ANNITA cause trouble sleeping or insomnia?

Insomnia (trouble sleeping) is included in the adverse reaction documentation under the 'Psychiatric' system-organ class. While official documents list it as a potential effect, it is not classified as a common occurrence.


Q: Can ANNITA affect a person's mood or feelings?

Official documents list adverse reactions under the 'Psychiatric' category, which suggests potential effects on the nervous system and sleep patterns. However, they do not explicitly detail mood or feeling changes.


Q: Are there any specific foods or drinks to avoid while on ANNITA?

Regulatory labeling emphasizes that the medicine is required to be taken with food to ensure proper absorption. However, official information does not list any specific foods or non-alcoholic drinks that are advised to be avoided while on the medication.


Q: Is it safe to drink alcohol in moderation while taking ANNITA?

Based on regulatory data and interaction checkers, no specific interaction has been found between the medicine and alcohol. Determining the appropriateness of alcohol use during treatment is a consideration for the prescribing healthcare provider.


Q: What happens if ANNITA is taken with certain supplements or herbal products?

Official warnings advise that all prescription and nonprescription medicines, including herbal products, vitamins, and nutritional supplements, should be reviewed with a healthcare provider. This review is done so that the complete safety profile can be considered before use.


Q: Is ANNITA appropriate for use in older adults (seniors)?

Official guidance notes that the decreased frequency of liver, kidney, or heart function often seen in older adults is a factor for consideration during prescribing. This consideration addresses how the medicine is processed and any underlying health conditions.


Q: Why do some people say they feel tired after starting ANNITA?

Official adverse reaction documentation lists asthenia (weakness or lack of energy) and fatigue as potential effects. While these effects are documented, they are not categorized as common occurrences.


Q: What are the official warnings about driving or operating machinery while on ANNITA?

Official safety documentation lists dizziness and somnolence (drowsiness) as potential side effects. Due to these possible effects, tasks requiring mental alertness, such as driving or operating machinery, may be affected.


Q: What should I do if I think ANNITA is not working for me?

Regulatory information advises that a healthcare provider should be contacted if diarrhea symptoms persist after the full course of the medication is completed. This measure allows for a professional assessment of the treatment response.


Q: Is it possible for ANNITA to cause a rash?

Official post-marketing safety data includes reports of rash and urticaria (hives) as possible adverse reactions. Regulatory information advises that a healthcare professional be informed about any serious or unexpected adverse reactions, such as a rash.


Q: How long does ANNITA stay in the body after the last dose?

While official documents do not typically specify the exact number of hours the drug stays in the body, it is known to be rapidly converted into its active form, tizoxanide. This active metabolite is primarily cleared from the body through the urine, bile, and feces.


Q: Is ANNITA considered a controlled substance?

According to regulatory classification and the DEA Schedule, this medication is not designated as a controlled substance.


Q: What type of monitoring is usually needed when taking ANNITA?

Official warnings indicate that the patient’s progress should be checked by a healthcare provider during regular visits. This monitoring is done to assess the medication’s response and to check for the development of any unwanted effects.


Q: Is it true that ANNITA is sometimes prescribed for conditions not listed in the main uses?

The official FDA prescribing information strictly details indications only for diarrhea caused by Giardia lamblia and Cryptosporidium parvum in specific patient groups. Regulatory documents do not address uses outside of these approved indications.


Q: Can I take other medicines that cause drowsiness while on ANNITA?

Somnolence (drowsiness) is documented as a potential adverse reaction of this medicine. Due to this potential effect, the concurrent use of other medications that may also cause drowsiness is a factor for professional caution.


Q: Do different forms of ANNITA (e.g., tablet, capsule) work differently?

Official regulatory documents state that the tablet and oral suspension forms are not interchangeable and have different bioavailabilities (how much of the drug is absorbed). The suspension is required for specific age groups to ensure proper dosing.


Q: What is the difference between how the medication works and how I feel it works?

The medication works at a pharmacological level by interfering with the PFOR enzyme to deplete parasite energy. How a patient 'feels' it working relates to the clinical response, which official studies describe as symptom resolution and changes in parasite status.


Q: What should be done if an accidental overdose of ANNITA is suspected?

Limited information on accidental overdose is available in regulatory documents. Official guidance advises observation and providing symptomatic and supportive treatment; regulatory protocols define contacting a poison control center if an overdose is suspected.


Q: Does ANNITA affect blood sugar levels?

Official documentation notes a caution for use in patients with diabetes because the oral suspension formulation contains sucrose. Diabetes is also listed as a disease interaction to be considered by the prescribing professional.


Q: Why is my doctor asking me about my full medical history before prescribing ANNITA?

Official guidance requires healthcare providers to consider a patient’s full medical history, especially if conditions like liver disease, kidney disease, or immune system problems exist. This review is done because regulatory constraints exist for its use in certain populations.


Q: What if I am allergic to ingredients in other medications, does that affect taking ANNITA?

Official safety guidance advises that a healthcare provider be informed about all known allergies, including those to foods, dyes, preservatives, or animals. This information is required for the professional evaluation of the potential risk of an adverse reaction to any of the formulation's ingredients.


Q: What does 'contraindication' mean in the official documents for ANNITA?

A 'contraindication' is a medical term used in official documents to describe a condition or factor that prevents the use of a medicine. This restriction exists due to potential risk. For this medicine, a known hypersensitivity to any ingredient is listed as a contraindication.


Q: Can travel across time zones affect the schedule for taking ANNITA?

Regulatory instructions advise taking the medicine every 12 hours to maintain a constant level of the active substance in the bloodstream. Maintaining the required 12-hour interval is necessary even when traveling across different time zones.

Advertisements

How should ANNITA be stored and disposed of?

Storage Requirements

ANNITA (Nitazoxanide) tablets and the unsuspended powder for oral suspension must be stored at Controlled Room Temperature, defined as 20, C to 25, C (68, F to 77, F), with protection from excessive heat, moisture, and direct light. The container for both forms must be kept tightly closed and away from environments such as the bathroom.

Stability and Handling

The oral suspension, once mixed, may also be stored at room temperature but must not be frozen or refrigerated. This liquid suspension has a strict 7-day stability period, after which any unused portion must be discarded.

Disposal and Child Safety

All medication must be stored out of the sight and reach of children. Unneeded or expired ANNITA should be disposed of via an official medicine take-back program. If a take-back option is unavailable, the medication must be mixed with an undesirable substance before being sealed in a container and placed in household trash; this product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of ANNITA found in:

A-Z Index: